CliffBio
small molecule

AUVI-Q

EPINEPHRINE

Loss of exclusivityDecember 2037latest FDA-listed patent expiry
CompanyKaleo →See this company's full patent-cliff portfolio

Drug detail

Brand nameAUVI-Q
Active ingredientEPINEPHRINE
StrengthEQ 0.1MG/DELIVERY
Dosage formSOLUTION
RouteINTRAMUSCULAR, SUBCUTANEOUS
ModalitySmall molecule
FDA approvalNovember 2017
Marketing statusRX

Listed patents

PatentExpiresType
10688244December 2037product
10842938December 2037product
11771830December 2037product
8021344November 2029product
8226610April 2029product
8231573November 2028product
7947017March 2028product
8206360February 2027product
11590286December 2026product

More from Kaleo

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

AUVI-Q patent cliff — loss of exclusivity December 2037 | CliffBio